4basebio PLC (88Q.DE)
EUR 14.6
(0.0%)
EUR 14.6
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 7.38 Million GBP | 838.06% |
| 2022 | -1 Million GBP | 87.21% |
| 2021 | -7.82 Million GBP | 41.07% |
| 2020 | -13.28 Million GBP | -629.67% |
| 2019 | 2.5 Million GBP | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q4 | 7.38 Million GBP | 307.64% |
| 2023 FY | 7.38 Million GBP | 838.06% |
| 2023 Q2 | -3.55 Million GBP | -255.44% |
| 2022 FY | -1 Million GBP | 87.21% |
| 2022 Q4 | -1 Million GBP | 82.12% |
| 2022 Q2 | -5.59 Million GBP | 28.5% |
| 2021 FY | -7.82 Million GBP | 41.07% |
| 2021 Q4 | -7.82 Million GBP | 35.11% |
| 2021 Q2 | -12.06 Million GBP | 9.18% |
| 2020 Q4 | -13.28 Million GBP | -10.77% |
| 2020 FY | -13.28 Million GBP | -629.67% |
| 2020 Q2 | -11.99 Million GBP | 0.0% |
| 2019 FY | 2.5 Million GBP | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| BioNTech SE | -11.44 Billion EUR | 100.065% |
| CureVac N.V. | -360.92 Million EUR | 102.047% |
| Biotest Aktiengesellschaft | 571.3 Million EUR | 98.707% |
| Biotest Aktiengesellschaft | 571.3 Million EUR | 98.707% |
| BRAIN Biotech AG | -693 Thousand EUR | 1166.089% |
| Formycon AG | 2.45 Million EUR | -201.428% |
| Heidelberg Pharma AG | -37.6 Million EUR | 119.645% |
| Medigene AG | -5.72 Million EUR | 229.071% |